Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

“…It therefore represents the cornerstone endpoint of all our current therapeutic attempts. 1,25,[34][35][36][37][38][39][40] The level of HBV DNA suppression that should be attained in order to achieve these benefits is not well defined, but inferred that the lower, the better. Treatment-induced HBeAg loss and seroconversion to antiHBe characterises the induction of a partial immune control often leading to a low replicative phase of the chronic HBV infection.…”

Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study

“…Much hope for controlling HCC is placed with active prophylaxis before its occurrence. Fortunately, the occurrence and recurrence of HBV-related HCC can be reduced via active prophylaxis using anti-HBV treatments with nucleos(t)ide analogue (NA) and/or IFNa (4)(5)(6)(7)(8)(9)(10). It is, therefore, important to identify the HBV-infected patients who are more likely to develop HCC, allowing timely intervention in those who will benefit most.…”

Letter: is body‐mass index really associated with fibrosis regression during long‐term nucleoside analogue therapy in chronic hepatitis B?

“…2,3 In addition, several factors that may reduce the accuracy of FibroScan including ascites, elevated central venous pressure as well as obesity because fluid and adipose tissue attenuate the elastic wave. [3][4][5] Other factors that may also influence the test results, such as sex (men have higher liver stiffness values than women) and metabolic syndrome. 6 Thus, there might exist a potential for misclassification of fibrosis stages in the study.…”

“…Third, the proportion of chronic hepatitis B patients under nucleoside analogue treatment is increasing, ranging from 27% in Western centers 4 to 41% in Asian populations. 5 The availability of non-invasive methods of liver fibrosis measurements will allow the mass screening, assessment and surveillance of larger patient populations. Liver stiffness measurements are now recommended in different international guidelines, 6,7 and as the on-treatment chronic hepatitis B population continues to increase, we expect liver stiffness measurements will become the main adopted technique of liver fibrosis assessment in daily clinical care.…”